explore -WSS

explore

author：entertainment 2025-10-01 18:44:37 - browse：872

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： An innovative path out of biotech’s “valley of death”

Wikipedia

WSS

What Kate Middleton's cancer revelation might teach the world

Timeline: Special counsel's investigation into Trump's handling of classified documents

Faced with fears of OxyContin misuse, sales reps touted its safety

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

U.K. officials, researchers try to ease path for bespoke genetic treatments

Newly revealed memo details efforts to keep Trump in power following election loss

explore

explore

Wikipedia

Jerome Adams on the need for new antivirals for Covid

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Anesthesiologist group: stop taking Ozempic before surgery

Erich Jarvis studies song birds to learn about human stuttering

Trump demands the U.S. pay no more for drugs than other countries … again

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

After affirmative action ruling, medical educators look to 'holistic review'

Maui funeral service workers on devastation of fires: 'I'm in shock'

Apple is now the first public company to be valued at $3 trillion

Chinese researcher claims birth of first gene

leisure time

Faced with fears of OxyContin misuse, sales reps touted its safety

Large hospital system sues Multiplan for low

Who are the detained American citizens released from prison in Iran?

6 surprising facts about sugar

Readout Newsletter: Illumina, CRISPR, Regeneron

Mirador, a new biotech startup, launches with $400 million

entertainment

hotspot

Wikipedia

focus